Team

Manijeh Goldberg, PH.D., M.B.A., M.S.

CHIEF EXECUTIVE OFFICER

Manijeh is the Founder and CEO of Privo. She has over 20 years of experience in the biomedical industry, in large companies and five startups (one was acquired for $475M).  She has developed US Key Opinion Leader (KOL) relationships, successfully lobbied to get PRV111 into a large, NIH-funded clinical study, planned and executed training, and helped drive on-time trial enrollment. Additionally, Manijeh is driving the execution of a second-generation Privo’s products. Her current focus is to conduct clinical trials, get PRV111’s second-generation products through the FDA, and explore initiating a second US clinical trial. Additional responsibilities include business development, general management, and driving the overall success of Privo’s research and products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, and an MS in Computer Science and Mathematics.


James Mackay, PH.D

Chief Advisor

Dr. Mackay is the founder, president, and CEO of Aristea Therapeutics, an immunology company focused on developing treatments for orphan diseases. Prior to founding Aristea Therapeutics, Dr. Mackay led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He was President & CEO of Ardea Biosciences from 2013 to 2018. He set up an innovative model for Ardea that retained the biotech’s independence and accountability for the development of the gout franchise while developing a collaborative relationship with the parent company, AstraZeneca. Prior to Ardea Biosciences, Dr. Mackay was Global Product Vice President for Diabetes franchise at AstraZeneca where he played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. He held a number of senior roles in AstraZeneca’s Clinical Development Function including portfolio management of all AstraZeneca Clinical resources and budget worldwide and management of AstraZeneca’s strategic partnerships with drug development CROs.


Jack Malley

INTERIM CHIEF FINANCIAL OFFICER

Jack is a principal in Withum’s Boston office and leads their OASyS practice (Outsourced Accounting Systems and Services). Jack specializes with life science companies. He is an expert at assisting start-ups, investors, specialty lenders and established private and public companies in various stages of growth. Prior to joining the Firm, Jack was a partner with RBF, which joined Withum in August 2019.

Jack received his MBA with an Accounting and Finance concentration from Northeastern University and his B.A. in Economics from the College of the Holy Cross. He is a member of the American Institute of Certified Public Accountants (AICPA) and the Massachusetts Society of Certified Public Accountants (MSCPA). Additionally, Jack is a member of the Network for Excellence in Health Innovation, the Massachusetts Biotechnology Council and the New England Healthcare Executive Network.


Nishant Agrawal, MD

Chief Medical Advisor

Dr. Nishant Agrawal is the director of Head and Neck Surgical Oncology at the University of Chicago Medicine. Dr. Agrawal specializes in the management of patients with benign and malignant tumors of the head and neck. His work has achieved international recognition in the field of head and neck surgical oncology, and head and neck cancer genetics. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University. Dr. Agrawal’s lab is devoted to the study of the genetics and molecular diagnostics of head and neck cancer. The group has described the genomic landscape of head & neck squamous cell carcinoma, esophageal cancer and medullary thyroid cancer, and has developed assays using tumor DNA as a biomarker in saliva and plasma. His lab’s research is focused on the application of cancer genetics to design diagnostic approaches to reduce morbidity and mortality from head and neck cancer.


Sam Goldberger, MD, MBA

SR. CLINICAL MONITOR

Sam is a well-known reconstructive and plastic surgeon with significant experience in the removal of squamous cell carcinoma and other epithelium tumors. Sam received his medical doctorate degree from the Albert Einstein College of Medicine in New York. He holds an MBA from MIT Sloan School of Management and a BS from MIT’s School of Biology.  Sam has been practicing as a reconstructive surgeon since 1991 and has performed thousands of surgical procedures. In addition to his expertise in medicine, Sam is well-experienced in innovation, entrepreneurship, and growing successful business.


Joanna Ward

GMP MANUFACTURING

Over 30 years of experience in CMC strategy and manufacturing oversight across all development phases of biological and pharmaceutical products, ranging from pre-IND to commercial approvals of novel oncology therapies. Joanna holds a BSc in Plant biology from the University of Hull in the UK.

Expert in authoring CMC sections of IND, IMPD, PMDA, CFDA and BLA’s. Responsible for development of complex commercial and clinical supply chains with global logistics, including complex contract negotiations and execution.


Jeff Fellows

Regulatory Affairs

Jeff is a seasoned pharmaceutical industry professional with over 30 years of drug development experience leading regulatory development efforts ranging from pre-IND to post-approval. Experienced in strategic development across numerous product platforms and therapeutic areas covering both North America and Europe with extensive clinical trial application filings and health authority interactions. He has a B.S. in Microbiology from Oregon State University.


Scientific Advisors

John Ripple

John Ripple founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development, and capital fundraising activities.
He previously served as CEO of 5 venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen).

Mr. Ripple also held positions in business development, entrepreneur-in-residence, medical device marketing, and management consulting.  He started his career as an aerospace engineer at NASA.  He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), on the Board of Directors and Treasurer of the Children’s Melanoma Prevention Foundation, and as an advisor to the MIT Deshpande Center for Technological Innovation.

Mr. Ripple received a BS in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.


Nishant Agrawal, M.D.

Dr. Nishant Agrawal, is the director of Head and Neck Surgical Oncology at the University of Chicago Medicine. Dr. Agrawal specializes in the management of patients with benign and malignant tumors of the head and neck. His work has achieved international recognition in the field of head and neck surgical oncology, and head and neck cancer genetics. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University.


James Demetroulakos, M.D.

Dr. Demetroulakos is Chief of Otolaryngology/ Head and Neck Surgery at the North Shore Medical Center and Attending Staff at Mass General Hospital and Mass Eye and Ear Infirmary. He is an emeritus staff at Harvard Medical school and the Uniformed Services School of the Health Sciences.  James received his medical and undergraduate degrees from Brown University through their seven-year med program.


Bharat Yarlagadda M.D.

Dr. Bharat Yarlagadda is the director of the Head and Neck Cancer Center of the Lahey Cancer Institute in Burlington, MA. His clinical practice specializes in the care of patients with benign and malignant tumors of the head and neck, including robotic surgery of the head and neck and microvascular reconstruction. He serves on numerous quality and safety committees at Lahey Hospital and Medical Center, as well as an elected member of the Medical Executive Committee. He is an assistant professor of Otolaryngology-Head and Neck Surgery at Boston University School of Medicine, with a research focus on quality outcomes and surgical simulation.


Board Members

Manijeh Goldberg, PH.D., M.B.A., M.S.

CHAIRMAN OF THE BOARD

Manijeh is the Founder and CEO of Privo. She has over 20 years of experience in the biomedical industry, in large companies and five startups (one was acquired for $475M).  She has developed US Key Opinion Leader (KOL) relationships, successfully lobbied to get PRV111 into a large, NIH-funded clinical study, planned and executed training, and helped drive on-time trial enrollment. Additionally, Manijeh is driving the execution of a second-generation Privo’s products. Her current focus is to conduct clinical trials, get PRV111’s second-generation products through the FDA, and explore initiating a second US clinical trial. Additional responsibilities include business development, general management, and driving the overall success of Privo’s research and products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, and an MS in Computer Science and Mathematics.


James Mackay, PH.D

Independent Board Member

Dr. Mackay is the founder, president, and CEO of Aristea Therapeutics, an immunology company focused on developing treatments for orphan diseases. Prior to founding Aristea Therapeutics, Dr. Mackay led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He was President & CEO of Ardea Biosciences from 2013 to 2018. He set up an innovative model for Ardea that retained the biotech’s independence and accountability for the development of the gout franchise while developing a collaborative relationship with the parent company, AstraZeneca. Prior to Ardea Biosciences, Dr. Mackay was Global Product Vice President for Diabetes franchise at AstraZeneca where he played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. He held a number of senior roles in AstraZeneca’s Clinical Development Function including portfolio management of all AstraZeneca Clinical resources and budget worldwide and management of AstraZeneca’s strategic partnerships with drug development CROs.


Jane Hirsh

Ms. Hirsh was Founder, President, and CEO of Copley Pharmaceutical, Inc., a large, successful generic pharmaceutical company. During her tenure, the Company completed over 80 ANDAs and attained revenues of $160 million prior to its acquisition. In 1993, Hoechst Celanese Corporation, the chemical and drug concern, acquired 51 percent of Copley Pharmaceutical Inc. for $546 million. In 2000, Copley was sold to Teva Pharmaceuticals. Jane is a co-inventor on over 9 patent applications and has over 40 years of experience in the pharmaceutical and related healthcare industries. In 2003, Ms. Hirsh co-founded and served as Chairman of Collegium Pharmaceutical. As a specialty pharmaceutical company, Collegium focused on intellectual property development under jane’s leadership. Onset Therapeutics, a dermatological specialty company, was founded in 2007 as a subsidiary of Collegium and sold to Precision Dermatology in 2010. In addition, Jane has served on the Board of Trustees for Tufts University and the Museum of Science, Boston.  


Contact Us
close slider

Contact Us